Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Älmby Entreprenad Aktiebolag (”Älmby Entreprenad”)
Mandate

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Älmby Entreprenad Aktiebolag (”Älmby Entreprenad”)

September 28, 2021 M&A Real Estate and Construction Employment and Benefits EU, Competition and Regulatory Banking and Finance

Älmby Entreprenad is based in Älmhult, has 115 employees and has yearly sales around SEK 500 million. Älmby Entreprenad offers unique solutions in ground construction but also provides demolition and drilling services.

Vinge’s team consisted primarily of partner Christina Kokko and associates Manne Bergström, Carl Fredrik Wachtmeister, Nando Basic and Ellen Åkerdahl Flygt (M&A), Isak Willborg and Mario Saad (Agreements), Ebba Svenburg (Employment), Jolinn Uhlin (Banking & Finance), Karolina Cohrs and Ulf Pyk (Real Property & Environment), Johan Wahlbom and Victoria Fredén (Competition) and Sara Dahlros Sköld (VDR-assistant).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026